Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy NeoGenomics stock in Canada | $44.81
Own NeoGenomics shares in just a few minutes.
NeoGenomics Inc is a diagnostics & research business based in the US. NeoGenomics shares (NEO) are listed on the NASDAQ and all prices are listed in US Dollars. NeoGenomics employs 1,700 staff and has a trailing 12-month revenue of around USD$488.7 million.
How to buy shares in NeoGenomics
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – NEO – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Is it a good time to buy NeoGenomics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
What's in this guide?
- Can I buy shares in NeoGenomics?
- Has coronavirus impacted NeoGenomics shares?
- NeoGenomics shares summary
- Compare share dealing platforms
- Is NeoGenomics stock a buy or sell?
- NeoGenomics performance over time
- Can I short NeoGenomics shares?
- Are NeoGenomics shares over-valued?
- NeoGenomics's financials
- How volatile are NeoGenomics shares?
- Does NeoGenomics pay a dividend?
- Have NeoGenomics shares ever split?
- Other common questions
How has Coronavirus impacted NeoGenomics's stock price?
Since the stock market crash in March caused by coronavirus, NeoGenomics's stock price has had significant positive movement.
Its last market close was $44.81, which is 27.49% up on its pre-crash value of $32.49 and 118.91% up on the lowest point reached during the March crash when the stocks fell as low as $20.47.
If you had bought $1,000 worth of NeoGenomics stocks at the start of February 2020, those stocks would have been worth $750.62 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $1,390.45.
NeoGenomics stock priceUse our graph to track the performance of NEO stocks over time.
NeoGenomics shares at a glance
|Latest market close||$44.81|
|52-week range||$36.00 - $61.57|
|50-day moving average||$47.32|
|200-day moving average||$45.16|
|Wall St. target price||$56.45|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$0.61|
Compare online stock trading platforms
Note: The dollar amounts in the table below are in Canadian dollars.
NeoGenomics price performance over time
|1 week (2021-10-15)||3.30%|
|1 month (2021-09-23)||-10.27%|
|3 months (2021-07-23)||-1.97%|
|6 months (2021-04-23)||-11.57%|
|1 year (2020-10-23)||8.39%|
|2 years (2019-10-23)||127.23%|
|3 years (2018-10-23)||217.80%|
|5 years (2016-10-21)||490.38%|
Is NeoGenomics under- or over-valued?
Valuing NeoGenomics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of NeoGenomics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
NeoGenomics's P/E ratio
NeoGenomics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 72x. In other words, NeoGenomics shares trade at around 72x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
NeoGenomics's PEG ratio
NeoGenomics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 3.02. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into NeoGenomics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
NeoGenomics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $30 million.
The EBITDA is a measure of a NeoGenomics's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$488.7 million|
|Gross profit TTM||$186.4 million|
|Return on assets TTM||-0.32%|
|Return on equity TTM||7.96%|
|Market capitalisation||$5.3 billion|
TTM: trailing 12 months
Shorting NeoGenomics shares
There are currently 7.4 million NeoGenomics shares held short by investors – that's known as NeoGenomics's "short interest". This figure is 3.2% up from 7.2 million last month.
There are a few different ways that this level of interest in shorting NeoGenomics shares can be evaluated.
NeoGenomics's "short interest ratio" (SIR)
NeoGenomics's "short interest ratio" (SIR) is the quantity of NeoGenomics shares currently shorted divided by the average quantity of NeoGenomics shares traded daily (recently around 1.0 million). NeoGenomics's SIR currently stands at 7.24. In other words for every 100,000 NeoGenomics shares traded daily on the market, roughly 7240 shares are currently held short.
However NeoGenomics's short interest can also be evaluated against the total number of NeoGenomics shares, or, against the total number of tradable NeoGenomics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case NeoGenomics's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 NeoGenomics shares in existence, roughly 60 shares are currently held short) or 0.0626% of the tradable shares (for every 100,000 tradable NeoGenomics shares, roughly 63 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against NeoGenomics.
NeoGenomics share dividends
We're not expecting NeoGenomics to pay a dividend over the next 12 months.
Have NeoGenomics's shares ever split?
NeoGenomics's shares were split on a 1:100 basis on 16 April 2003. So if you had owned 100 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your NeoGenomics shares – just the quantity. However, indirectly, the new 9900% higher share price could have impacted the market appetite for NeoGenomics shares which in turn could have impacted NeoGenomics's share price.
NeoGenomics share price volatility
Over the last 12 months, NeoGenomics's shares have ranged in value from as little as $36 up to $61.57. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while NeoGenomics's is 0.6646. This would suggest that NeoGenomics's shares are less volatile than average (for this exchange).
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates in two segments, Clinical Services and Pharma Services. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited; and has collaboration with Elevation Oncology to expand genomic testing for NRG1 fusions across solid tumors. The company was founded in 2001 and is headquartered in Fort Myers, Florida.
Stocks similar to NeoGenomics
Frequently asked questions
NeoGenomics in the news
Premarket Movers: dLocal, TaskUs, Sarepta Therapeutics
NeoGenomics' Liquid Biopsy Subsidiary Inivata Announces Clinical Collaboration With Princess Margaret Cancer Center for the Use of Its Liquid Biopsy Assays
NeoGenomics' : Liquid Biopsy Subsidiary Inivata Announces Clinical Collaboration With Princess Margaret Cancer Center for the Use of Its Liquid Biopsy Assays
More on investing
Stock trading doesn’t have to be expensive. Using Finder’s proprietary algorithm, we’ve identified the best cheap Canadian and US stocks to buy now.Read more…
Steps to owning and managing Cue Health stocks, with 24-hour and historical pricing before you buy.Read more…
Steps to owning and managing ARBK stock, with 24-hour and historical pricing before you buy.Read more…
More guides on Finder
How to buy AirSculpt Technologies (AIRS) stock in Canada when it goes public
Everything we know about the AirSculpt Technologies IPO, plus information on how to buy in.
How to buy Candela Medical (CDLA) stock in Canada when it goes public
Everything we know about the Candela Medical IPO, plus information on how to buy in.
How to buy Ensemble Health Partners (ENSB) stock in Canada when it goes public
Everything we know about the Ensemble Health Partners IPO, plus information on how to buy in.
How to buy Fluence Energy (FLNC) stock in Canada when it goes public
Everything we know about the Fluence Energy IPO, plus information on how to buy in.
How to buy GlobalFoundries (GFS) stock in Canada when it goes public
Everything we know about the GlobalFoundries IPO, plus information on how to buy in.
How to buy LianBio (LIAN) stock in Canada when it goes public
Everything we know about the LianBio IPO, plus information on how to buy in.
How to buy Rent the Runway (RENT) stock in Canada when it goes public
Everything we know about the Rent the Runway IPO, plus information on how to buy in.
How to buy Solo Brands (DTC) stock in Canada when it goes public
Everything we know about the Solo Brands IPO, plus information on how to buy in.
How to buy Udemy (UDMY) stock in Canada when it goes public
Everything we know about the Udemy IPO, plus information on how to buy in.
How to buy Arteris (AIP) stock in Canada when it goes public
Everything we know about the Arteris IPO, plus information on how to buy in.